Juraj Adamik, PhD Research Scientist Research Biography Juraj Adamik, PhD, is a research scientist at PICI and visiting research associate at the Microbiology and Immunology Department at the University of California, San Francisco. Under the leadership of Dr. Lisa H. Butterfield, Adamik investigates the effectiveness of dendritic cell cancer vaccines in evoking T cell-specific responses to tumor antigens in melanoma and hepatocellular carcinoma. Prior to joining PICI, Adamik was a postdoctoral associate at the UPMC Hillman Cancer Center, University of Pittsburgh School of Medicine, Division of Hematology/Oncology. He investigated transcriptional and epigenetic changes in bone marrow cellular compartments in the context of hematologic malignancies and metastatic breast cancer. During his PhD research at Duquesne University in Pittsburgh, Adamik’s work contributed to a key discovery of Krebs Cycle metabolite succinate as an inflammatory danger signal regulating metabolic reprogramming of LPS-activated macrophages published in Nature.